Article Text

Download PDFPDF
Randomised controlled trial
N-3 fatty acids did not reduce major cardiovascular events in patients with dysglycaemia
  1. Daan Kromhout
  1. Division of Human Nutrition, Wageningen University and Research Centre, Wageningen, The Netherlands
  1. Correspondence to : Daan Kromhout
    Division of Human Nutrition, Wageningen University and Research Centre, Biotechnion, Bomenweg 2, 6703 HD Wageningen, The Netherlands; daan.kromhout{at}

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Commentary on OpenUrlCrossRefPubMedWeb of Science


N-3 fatty acids have beneficial effects on elevated triglyceride levels, impaired endothelial function, inflammation, atherosclerotic plaque and severe arrhythmias. Prospective cohort studies have shown a lower risk of cardiovascular events among persons who consumed fish regularly. These studies were followed by clinical trials evaluating the effects of supplements with the fish fatty acids eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) in patients with a history of cardiovascular disease. The ORIGIN trial was the first large trial testing the hypothesis that long-term supplementation with n-3 fatty acids reduces cardiovascular events in dysglycaemic patients.


Patients with type 2 diabetes, impaired fasting glucose or impaired glucose tolerance were recruited from September 2003 through December 2005. A …

View Full Text


  • Competing interests None.